Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (201-210 of 302) with videos related to

Pageof 31
Sort By:
European Journal of Public Health|July 4, 2025
Basing healthcare decisions on value: patient-reported outcomes for patients diagnosed with breast cancer in a European cohortAnia Gorostiza, Jon Cacicedo, Itxaso Alayo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2006
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomographyCaroline Rousseau, Anne Devillers, Christine Sagan, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
Breast Cancer Research and Treatment|February 7, 2018
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trialWolfgang Janni, Emilio Alba, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsHope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
The Lancet. Oncology|November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trialHervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
Journal of Adolescent and Young Adult Oncology|July 7, 2026
Prospective SAJAC Study of Rehabilitation for Adolescents and Young Adults with Cancer in a Comprehensive Cancer CenterEmmanuelle Bompas, Audrey Blanc Lapierre, Josselin Sebille, et al.
The Oncologist|July 16, 2013
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive markerCristina Saura, Ling-Ming Tseng, Stephen Chan, et al.
Pageof 31

Showing results (201-210 of 302) with videos related to

Sort By:
Pageof 31
European Journal of Public Health|July 4, 2025
Basing healthcare decisions on value: patient-reported outcomes for patients diagnosed with breast cancer in a European cohortAnia Gorostiza, Jon Cacicedo, Itxaso Alayo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2006
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomographyCaroline Rousseau, Anne Devillers, Christine Sagan, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
Breast Cancer Research and Treatment|February 7, 2018
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trialWolfgang Janni, Emilio Alba, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|December 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsHope S Rugo, Catherine H Van Poznak, Patrick Neven, et al.
The Lancet. Oncology|November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trialHervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
Journal of Adolescent and Young Adult Oncology|July 7, 2026
Prospective SAJAC Study of Rehabilitation for Adolescents and Young Adults with Cancer in a Comprehensive Cancer CenterEmmanuelle Bompas, Audrey Blanc Lapierre, Josselin Sebille, et al.
The Oncologist|July 16, 2013
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive markerCristina Saura, Ling-Ming Tseng, Stephen Chan, et al.
Pageof 31